In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alnara Pharmaceuticals

Latest From Alnara Pharmaceuticals

Stockwatch: 2017, Year Of The Dog

News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.

Commercial Clinical Trials

Westphal's Flex Pharma raises $40m for muscle cramp supplement

Serial biotechnology entrepreneur Christoph Westphal, who co-founded companies such as Alnylam Pharmaceuticals and Verastem, now is backing a private firm that's raised $40m to develop a nutritional supplement to relieve muscle cramps.

Cancer Orthopedics

Anthera acquires troubled Sollpura from Lilly

Anthera Pharmaceuticals acquired Sollpura (liprotamase), a non-porcine pancreatic enzyme replacement therapy (PERT) with a long and troubled history in exocrine pancreatic insufficiency (EPI), from Eli Lilly for an undisclosed price.

Gastrointestinal Dermatology

As Some VCs Refill, Others Are Running Out Of Gas

Life science VCs are posting strong across-the-board returns, allowing some firms to raise new funds larger than their prior vehicles. Still, the contraction that began nearly five years ago continues to thwart other firms’ efforts to press on through hard times.

BioPharmaceutical North America
See All

Company Information